This study was designed to examine the effects of a healer seeing chronically ill patients in a large semirural practice. The 57 patients were allocated alternately either to receive ten weekly healing sessions or to become waiting-list controls.
INTRODUCTION
Chronic symptoms that do not respond to treatment are frustrating to both patient and general practitioner (GP). Some patients consult spiritual healers for these symptoms and a few are referred by their GPs. 'Healing' involves an intention on the part of the healer to catalyse the healing process within a patient without using any known physical means of intervention. Thus defined, research on healing may tell us about the possible role of healers in modern healthcare and have implications for the potential but neglected1 role of the doctor as carer and healer.
There have been reviews on the subject of spirituality Study patients received ten weekly forty-minute healing sessions, while their parallel controls had their healing , post myocardial infarction, post head deferred for 12 weeks (increased to 24 weeks for the 12 control patients in the second half of the study). The running of study and control patients in parallel excluded seasonal factors. Study patients were told that they were going to see a 'healer' rather than a faith healer or spiritual healer. The healing session would include a discussion between healer and patient about symptoms and general wellbeing. The main part of the treatment would involve the healer applying her hands close to the patient and slowly moving them over the entire body while visualizing the passage of white light passing through her and into the patient. Each session was accompanied by relaxing music.
Control patients continued to receive conventional care from their GP.
Assessments for control and study patients were done at the beginning of the trial and at three months. Further assessments at six months were done for all study and half the control patients. In an interview with the research nurse, patients would score their symptoms on a scale from 
Symptom change score' Study
*Patients scored their symptoms on a scale of 0-10. Comparison of study and control groups is on an intention-to-treat basis. Thus month 0-month 3 and month 0-month 6 includes only the 27 and 20 patients, respectively, who completed the first three and six months of the trial tPatients were asked to rate any change in symptoms at three and six months: -4 (couldn't be worse), -3 (very much worse), -2 (much worse), -1 (slightly worse), 0 (same), +1 (slightly better), +2 (much better), +3 (very much better), +4 (no symptoms any more) IQR=interquartile range symptoms could thus be quantified by comparing different symptom scores at different times. Perceived change in symptoms was also measured by asking patients directly to report any change that they had noticed in their symptoms at three and six months compared with how they felt before ( Consultation rates for the year previous to entering the study and for the six months in the year after entry were recorded for study and control patients. The researcher scanning the notes was blinded. Self reports on current medication were also noted at the beginning of this trial for study and control patients and also at three month followup.
Statistical results were presented either parametrically or non-parametrically as determined by the chi-square goodness-of-fit test. Those approximating the normal distribution were analysed as means and standard deviations and between-group comparisons of changes over three and six months were made by t-tests. Non-parametric data were summarized by medians and interquartile ranges (IQRs) and their between-group differences assessed by the MannWhitney U test. Estimates of these between-group differences were calculated and presented with a 95% confidence interval (based either on the t-distribution or the distribution of the Mann-Whitney U test statistic as appropriate). The research statistician was sent results directly by the research nurse and therefore not blinded to data assignment. The study was approved by an ethics committee. RESULTS 57 patients entered the trial (30 study, 27 control). 73 patients had been originally referred by their GP, of whom 72 were eligible, but 9 declined to enter before allocation Of the 57 patients who entered the trial proper, 6 fell out of the study during the first three months (3 study patients before receiving any healing and 3 controls). Between three and six months 2 study patients were lost to follow-up while all 12 control patients, who had had their healing deferred for six months, remained in the trial.
There were more women than men in both groups, reflecting their increased consultation rate in general practice. Study and control groups appeared to be similar with respect to symptoms and their duration, and around half the patients had had symptoms for at least 5 years. The two groups were also well matched for scores on all main indices at the beginning of the trial (Tables 1-3 ).
Symptoms (see Table 2 ) After three months of healing, study patients showed an improvement in median symptom score of 1.0 (IQR 0 to 3), compared with a median change of 0 for controls (IQR -1 to 1). This treatment difference was statistically significant (T=437.5, P<0.05), estimated as 2.0 (CI 0, 3) but there was no significant difference between study and control groups at six months.
Of the 27 study patients who had had healing, 5 judged that their symptoms were the same, 8 felt slightly better, 7 felt much better, 6 felt very much better and 1 claimed to have no further symptoms at all two weeks after completion of healing. Asked whether they thought their symptoms had improved or deteriorated, there appeared to be a difference between the two groups favouring the study patients (study group, median score 1, IQR 1.0 to 3.0; controls, median score 0, IQR -1.0 to 0, T=570.5, P<0.01). The treatment difference was estimated as 2.0 (CI 1.0, 3.0) and study and control patients were still significantly different in this respect at the six-month stage (T=144, P<0.05).
Affective state (see Table 3 ) Study patients showed improvement in anxiety and depression scores at three months, with little change in control scores. At the three-month assessment, the HAD anxiety scale showed a median reduction of 4.0 (IQR 1.0 to 5.0) in study patients, compared with a median of 0 (IQR -2.0 to 2.0) in controls. This treatment difference was significant (T=523.5, P < 0.01 ) and was estimated to be 3.0 (CI 2.0, 5.0).
The HAD depression scale showed similar results, with study patients improving by a median of 2.0 (IQR 0 to 4.0), compared with 0 for controls (IQR range 0 to 1.0). This difference was also statistically significant (T=445.0, P<0.05) and estimated as 2.0 (CI 0 to 3.0).
At the six-month stage (three months after completion of healing) the improvement in study patients was again better than that in the controls for both anxiety and depression (anxiety, T=226.5, P<0.01; depression, T=207.0, P<0.05). Treatment differences were estimated to be 3.0 (CI 0 to 4.0) and 2.0 (CI 0 to 4.0), respectively. General function (Table 4) Mean baseline values on the Nottingham Health Profile were 11.5 (SD 8.38) for study patients and 11.7 (6.86) for controls. After three months, study patients showed a mean improvement of 4.7 (4.97) after healing, compared with 1.3 (3.70) for controls. This difference between the groups was statistically significant (t=2.74, P <0.01) and estimated as 3.4 (CI 0.89, 5.90). At six months, study patients had maintained an improvement on the Nottingham Health Profile but the treatment difference estimated as 1.8 (CI -1.70, 5.30) was not statistically significant (t=1.04).
Immunological changes (Table 5) The percentage of natural killer cells (CD56 and CD 16) did not greatly alter throughout the study for either study or control patients. Average levels of CD56 were around 20% for study patients and 19% for controls, while levels of 
Consultation rates and medication
Study and control patients were well matched with regard to consultation rates, which were around 12 per annum compared with the practice average of 3.4 per annum. Both study and control patients showed a small reduction in consultation rate but there was no significant difference between the two groups. Patient self reports on changes in current medication (Table 6 ) suggested a greater likelihood of their reducing medical treatment if they were in the study group (P <0.05, x2). These self reports were, however, uncorroborated.
DISCUSSION
This is the first research from primary care to explore the role of a healer in a controlled study. The results suggest that the intervention may lead to an improvement in the symptoms, affective state and general function of chronically ill patients. 52% of patients felt substantially better after healing, having been unresponsive to previous treatments, while none felt worse. Improvements in the affective state of patients, detected two weeks after the healing regimen, were still in evidence three months later, in line with the long-term effects seen in the Lourdes study8. Indeed, comparison of three-month and six-month results suggests that effects on general wellbeing are better maintained in the long term than improvements in specific Control (n=24) 15 2 7 symptoms, though long-term results in this study must be interpreted cautiously because of the small number of patients at this stage. There was no change in immunological response with healing. Early impressions5 that healing might reduce consultation rates have not been confirmed in this controlled study. An apparent reduction in medication after healing will require further research.
Because of its methodological limitations, this trial should be regarded as a hypothesis-generating rather than hypothesis-testing study. These limitations include the use of sequential rather than random allocation, the lack of blinding (of patient, research nurse or data analyst), the use of waiting list controls and the small number of control patients at the six-months stage. This research does, however, provide a strong case for a good-quality randomized and possibly multicentre trial based in general practice. The present research does not (and was not designed to) distinguish between any 'specific' effects of the healer and those that might have been brought about by other factors such as relaxation and the relationship between therapist and patient. To make such a distinction, a future trial would need to blind the patient (e.g. by use of a stooge or a screen between patient and healer) but this would not be feasible in general practice and would still leave questions unanswered (e.g. a stooge might turn out to have healing ability). Alternatively a future trial might compare healing with a standard therapy given for a specific condition (such as arthritis or psoriasis/eczema) in which changes could be measured objectively. Such a study could also include quality of life and general function measures of the kind used in the present one, and examine the comparative long-term effects of each therapy. It would be useful also to compare the cost effectiveness of healing and the conventional therapy (including costs of therapy, changes in concurrent medication, rates of consultation/ referral and days off work) as a means of assessing the role of healing, if any, in a cost-conscious National Health Service.
CONCLUSION
For many of the patients, healing appeared to be an effective treatment whatever its method of working. None reported any adverse effects and the treatment was relatively inexpensive. The size of effect seen in these chronic patients implies that GPs themselves may have an important therapeutic role quite apart from the prescription pad or the referral letter, and that we should not underestimate our potential but currently unfashionable role as 'physician healers'.
